Monopar Therapeutics

Monopar Therapeutics develops ALXN1840, a late-stage candidate for Wilson disease, and radiopharmaceuticals for advanced cancer imaging and treatment, including MNPR-101-Zr in Phase 1 imaging studies and MNPR-101-Lu and MNPR-101-Ac in early-stage therapeutic development.